KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 6,669 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 6,669 shares of the company’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $11.97, for a total value of $79,827.93. Following the transaction, the chief executive officer now owns 287,811 shares of the company’s stock, valued at approximately $3,445,097.67. This trade represents a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Trading Up 0.6 %

KALV opened at $11.99 on Tuesday. The stock has a market cap of $592.52 million, a PE ratio of -3.29 and a beta of 0.76. KalVista Pharmaceuticals, Inc. has a 1 year low of $7.30 and a 1 year high of $15.50. The stock’s 50 day simple moving average is $9.38 and its 200-day simple moving average is $10.28.

Institutional Trading of KalVista Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Aquatic Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the fourth quarter valued at approximately $44,000. Tower Research Capital LLC TRC grew its position in KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 5,502 shares during the period. Legal & General Group Plc grew its position in KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 1,494 shares during the period. Martin Worley Group bought a new stake in KalVista Pharmaceuticals in the fourth quarter valued at $86,000. Finally, China Universal Asset Management Co. Ltd. grew its position in KalVista Pharmaceuticals by 24.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company’s stock valued at $87,000 after acquiring an additional 2,043 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KALV. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Cantor Fitzgerald reiterated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, December 9th. TD Cowen began coverage on KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target for the company. Citizens Jmp upgraded KalVista Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 31st. Finally, Bank of America started coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price target for the company. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, KalVista Pharmaceuticals has an average rating of “Buy” and a consensus target price of $23.80.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).